Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris 11:35:51 2024-05-21 am EDT 5-day change 1st Jan Change
90 EUR +0.94% Intraday chart for Sanofi -1.84% +0.27%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sanofi Partners with Microsoft-Backed OpenAI, Formation Bio to Develop Drugs with AI MT
Sanofi: cooperation with Formation Bio and OpenAI CF
Sanofi Teams Up with Formation Bio, OpenAI for Drug Development AI Software MT
France's Sanofi Partners With OpenAI to Accelerate Drug Development DJ
Sanofi partners with OpenAI, Formation Bio on AI-driven drug development RE
Press Release Sanofi, Formation Bio And Openai Announce First-In-Class Ai Collaboration RE
Sanofi: positive data for Dupixent in COPD CF
Regeneron, Sanofi Disclose Positive Results for Lung Disease Treatment Candidate MT
Shah Capital ends campaign against Novavax board after Sanofi deal RE
Shah Capital withdraws campaign against Novavax directors after Sanofi deal RE
Transcript : Sanofi Presents at Bank of America Health Care Conference 2024, May-15-2024 08:00 AM
Global markets live: Apple, Sony, Vodafone, Booking, Walmart... Our Logo
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading MT
Sanofi India's Net Profit Slides in Q1 MT
Novavax Shares Pop Another 50% Following Sanofi Deal DJ
Top Midday Stories: Return of 'Roaring Kitty' Lifts GameStop Shares; Intel, Apollo Near Deal on Ireland Plant; BHP Latest Offer Rejected by Anglo American; Squarespace Acquired by Permira; Amazon Autonomous Driving Under Probe MT
CAC40: symbolic losses, 'volat' rises at W-Street CF
Trending : Fulcrum Therapeutics, Sanofi in Losmapimod Licensing Deal DJ
Sartorius Partners With Sanofi for Biomanufacturing Platform MT
France Secures $16 Billion From Microsoft, Amazon and Others at Foreign Investment Summit -- 2nd Update DJ
France Secures $16 Billion From Microsoft, Amazon and Others at Foreign Investment Summit -- Update DJ
Fulcrum Therapeutics, Sanofi Sign Licensing Deal for Facioscapulohumeral Muscular Dystrophy Treatment MT
Sanofi to Invest $1.08 Billion Into Three French Drug Manufacturing Sites MT
Sanofi Signs License Deal for Rare Genetic Muscle Disease Drug MT
Sanofi to Invest $1.08 Billion Into 3 French Drug Manufacturing Sites MT
Chart Sanofi
More charts
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
90 EUR
Average target price
108.3 EUR
Spread / Average Target
+20.37%
Consensus
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. News Sanofi
  5. IGM Biosciences, Sanofi Narrow Partnership to Focus on Potential Immunology and Inflamation Targets
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW